This observation was extended to mechanistically diverse anti-cancer agent (5-FU, valproic acid and irinotecan); suggesting that NFATc1 promotes a broad resistance to chemotherapeutic drugs in pancreatic cancer. Here, NFATC1 is linked to familial pancreatic carcinoma.